This article is more than 5 years old. Information may no longer be current.

Nicox reports third quarter highlights

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox had cash and cash equivalents of 47.1 million euros as of Sept. 30 compared with 20.4 million euros as of June 30, according to a company press release.

The company reported no revenues for the third quarter due to the fact that a nonrefundable $6 million payment from Eyevance Pharmaceuticals for exclusive licensing rights to Zerviate (cetirizine ophthalmic solution) was not immediately recognizable as revenue.

Nicox recently entered collaborations with Re-Vana Therapeutics and pSivida to explore the potential for sustained-release formulations of its stand-alone nitric oxide donors.